Skip to content
  • Select your language
    • English
    • French
    • Spanish
    • Italian
    • German
    • Japanese
    • Simplified Chinese

Language

Login/ Logout
Register
JP – Journey to a New Era for Alzheimer’s Disease
  • Home
  • About the Program
  • Faculty
  • Ask a Question
Home About the Program Faculty Ask a Question

AD/PD™️ 2024 Lisbon, Portugal – March 5 – 9, 2024

Home > Conference > AD/PD™️ 2024 Lisbon, Portugal – March 5 – 9, 2024

AD/PD focuses on basic science and translational and clinical research in Alzheimer’s disease and Parkinson’s disease, bringing key advances in disease mechanisms, innovative therapies, and diagnostic biomarkers.

Conference Content

News Nuggets
ADPD 2024 – ドナネマブにおいてアデュカヌマブと比較して18ヵ月後のアミロイドクリアランスが改善
ADPD 2024 – ベースラインのアミロイドはドナネマブ治療によるアミロイドクリアランスの最重要予測因子
AD/PD™️ 2024 – 研究では、P-タウ217単独およびP-タウ231との組み合わせによる予測能力が強調されている
AD/PD™️ 2024 – ニュースフラッシュ 4 – ADにおけるレカネマブの疾患修飾効果、24ヵ月間持続
AD/PD™️ 2024 – Nugget 5 – データモデリングがドナネマブの有効性と安全性のバランスに光を当てる
Breakfast Bytes - Video
AD/PD™️ 2024 – Breakfast Bite – Highlights of latest research on fluid biomarkers
AD/PD™️ 2024 – Breakfast Bite – Highlights research on earlier treatment with anti-amyloid immunotherapies
Breakfast Bytes - Podcast
AD/PD™️ 2024 – Breakfast Bite 1 – Podcast
AD/PD™️ 2024 – Breakfast Bite 2 – Podcast
Content Menu

Click to Provide Flash Feedback

12345678910
1 = poor, 10 = excellent
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Strongly disagreeDisagreeNeutralAgreeStrongly agree
YesNo
This field is for validation purposes and should be left unchanged.

このコンテンツが気に入りましたか?

このプログラムに参加すると、プレミアム認定コンテンツにアクセスし、年間を通してCMEクレジットを取得することができます。

今すぐ登録

Privacy Policy
Terms and Conditions

Contact us: ime@springer.com

This activity is supported by an educational grant from Lilly.

This content was last updated on 3rd March 2024

Follow Us:

  • LinkedIn
  • Facebook
  • X

Manage cookie preferences

© 2024 Springer Healthcare Ltd | Website by Arttia Creative